MedTrace Logo

A Study of Gaboxadol in Primary Insomnia

NCT00209963 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2007-03-30

No results posted yet for this study

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Conditions

  • Primary Insomnia

Interventions

DRUG

Gaboxadol

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Please contact: Annelies van der Hammen Legters · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2005-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209963 on ClinicalTrials.gov